S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

AngioDynamics Shares Plummet Following CEO Transition

Investors reacted sharply to a leadership change at AngioDynamics on Thursday, sending the company’s stock price tumbling 20% to $11.34 by midday. The market’s sudden retreat underscores ongoing instability for the medical-technology firm, which has now seen its share value decline 12% since the start of the year.

AngioDynamics Shares Plummet Following CEO Transition

Eric Honroth, formerly the global president of life science at the Swedish medical-technology firm Getinge, is set to take the helm on November 2. He will replace current chief executive James Clemmer, who will remain with the company in a consulting role to facilitate the handoff. Honroth will also secure a seat on the board of directors as part of the executive transition.

Under the terms of his new contract, Honroth will command a base annual salary of $735,000. His compensation package includes an annual performance bonus targeted at 95% of his base pay, reflecting the board's expectations for the incoming leadership despite the immediate negative market response.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!